Alkermes plc.

ALKS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001520262

Price chart

Open-market purchases and sales by ALKS insiders, newest first.

Insider trades
Filed (ET)Trade dateInsiderTransactionSharesAvg priceValueShares afterHolding changeFiling
Sep 3, 20266:32 PM ETSep 3, 2026Gaffin David JosephEVP, CLO, Alkermes, Inc.SSaleOrdinary Shares−2.03K$48.01−$97.65K223.42K−0.9%SEC10b5-1
Sep 1, 20267:08 PM ETSep 1, 2026Hopkinson Craig C.EVP R&D, Chief Medical OfficerSSaleOrdinary Shares−9K$46.986−$422.87K65.39K−12.1%SEC10b5-1
Aug 17, 20266:53 PM ETAug 17, 2026Nichols Christian ToddSVP, Chief Commercial OfficerSSaleOrdinary Shares−7.58K$49.2261−$372.94K102.19K−6.9%SEC10b5-1
Aug 3, 20267:16 PM ETAug 3, 2026snyderman nancy lynn MDDirectorSSaleOrdinary Shares−44.47K$50.348−$2.24M15.4K−74.3%SEC
Aug 3, 20267:12 PM ETAug 3, 2026Hopkinson Craig C.EVP R&D, Chief Medical OfficerSSaleOrdinary Shares−9K$48.58−$437.22K69.39K−11.5%SEC10b5-1

The largest institutional positions in ALKS at the end of Q2 2026.

Institutions holding ALKS in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
BlackRock, Inc.29,235,739$1.53B0.02%+921,329+3.3%Added
BAKER BROS. ADVISORS LP10,012,267$524.59M2.63%00.0%Unchanged
VANGUARD PORTFOLIO MANAGEMENT LLC9,490,818$497.27M0.02%−20,294−0.2%Reduced
STATE STREET CORP9,160,575$479.97M0.01%−304,711−3.2%Reduced
VANGUARD CAPITAL MANAGEMENT LLC7,515,025$393.75M0.01%+87,628+1.2%Added